Exact Mass: 477.2879
Exact Mass Matches: 477.2879
Found 500 metabolites which its exact mass value is equals to given mass value 477.2879,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Gentamicin
A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation). [PubChem] D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use S - Sensory organs > S03 - Ophthalmological and otological preparations > S03A - Antiinfectives > S03AA - Antiinfectives J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors C254 - Anti-Infective Agent > C258 - Antibiotic
EPOTHILONE C
An epothilone that is 1-oxacyclohexadec-13-ene-2,6-dione which is substituted by hydroxy groups at positions 4 and 9, methyl groups at positions 5, 5, 7, and 9, and by a (1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl group at position 16 (the 4S,7R,8S,9S,13Z,16S stereoisomer).
LysoPE(0:0/18:2(9Z,12Z))
LysoPE(0:0/18:2(9Z,12Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/18:2(9Z,12Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(18:2/0:0)
LysoPE(18:2(9Z,12Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(18:2(9Z,12Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
1'-O-Acetylpaxilline
1-O-Acetylpaxilline is a mycotoxin from the mycelium of Emericella striata. Mycotoxin from the mycelium of Emericella striata
(5Z)-7-[(1R)-2-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine
(5Z)-7-[(1R)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1R)-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z)-7-[(1R,2E,5S)-5-Hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine
(5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z)-7-{2-[(1E,3R)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine
(5Z)-7-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-{2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z)-7-[(1S,2S,5R)-5-[([1,1'-Biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl]hept-4-enoic acid
Epothilone C
Etimicin
(-)-PF1163A|(3S,10R,13S)-3-(4-(2-hydroxyethoxy)benzyl)-13-((S)-2-hydroxypentyl)-4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione|(3S,10R,13S)-3-[4-(2-hydroxyethoxy)benzyl]-13-[(S)-2-hydroxypentyl]-4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione|PF 1163A|PF1163A
20-ethyl-7,8-methanediyldioxy-1alpha,14alpha,16beta-trimethoxy-4-methoxymethyl-aconitan-6-one|Dehydrodelcorin|dehydrodelcorine|O-methyl-ilidine
3beta-acetylnorerythrophlamide|3beta-O-acetylnorerythrophlamide
C28H35N3O4_(1R,3S,5R,7S,12S)-4,4,4,4,12,14-Hexamethyl-4H,13H-spiro[9,14-diazatetracyclo[5.5.2.0~1,9~.0~3,7~]tetradecane-5,8-[1,4]dioxepino[2,3-g]indole]-9,13(10H)-dione
Ala Phe Ile Lys
Ala Phe Ile Gln
Ala Phe Lys Ile
Ala Phe Lys Leu
Ala Phe Leu Lys
Ala Phe Leu Gln
Ala Phe Gln Ile
Ala Phe Gln Leu
Ala Ile Phe Lys
Ala Ile Phe Gln
Ala Ile Lys Phe
Ala Ile Gln Phe
Ala Lys Phe Ile
Ala Lys Phe Leu
Ala Lys Ile Phe
Ala Lys Leu Phe
Ala Lys Pro Tyr
Ala Lys Tyr Pro
Ala Leu Phe Lys
Ala Leu Phe Gln
Ala Leu Lys Phe
Ala Leu Gln Phe
Ala Pro Lys Tyr
Ala Pro Tyr Lys
Ala Gln Phe Ile
Ala Gln Phe Leu
Ala Gln Ile Phe
Ala Gln Leu Phe
Ala Tyr Lys Pro
Ala Tyr Pro Lys
Phe Ala Ile Lys
Phe Ala Ile Gln
Phe Ala Lys Ile
Phe Ala Lys Leu
Phe Ala Leu Lys
Phe Ala Leu Gln
Phe Ala Gln Ile
Phe Ala Gln Leu
Phe Gly Arg Val
Phe Gly Val Arg
Phe Ile Ala Lys
Phe Ile Ala Gln
Phe Ile Lys Ala
Phe Ile Gln Ala
Phe Lys Ala Ile
Phe Lys Ala Leu
Phe Lys Ile Ala
Phe Lys Leu Ala
Phe Lys Pro Ser
Phe Lys Ser Pro
Phe Leu Ala Lys
Phe Leu Ala Gln
Phe Leu Lys Ala
Phe Leu Gln Ala
Phe Asn Val Val
Phe Pro Lys Ser
Phe Pro Ser Lys
Phe Gln Ala Ile
Phe Gln Ala Leu
Phe Gln Ile Ala
Phe Gln Leu Ala
Phe Arg Gly Val
Phe Arg Val Gly
Phe Ser Lys Pro
Phe Ser Pro Lys
Phe Val Gly Arg
Phe Val Asn Val
Phe Val Arg Gly
Phe Val Val Asn
Gly Phe Arg Val
Gly Phe Val Arg
Gly Arg Phe Val
Gly Arg Val Phe
Gly Val Phe Arg
Gly Val Arg Phe
His Lys Pro Pro
His Pro Lys Pro
His Pro Pro Lys
Ile Ala Phe Lys
Ile Ala Phe Gln
Ile Ala Lys Phe
Ile Ala Gln Phe
Ile Phe Ala Lys
Ile Phe Ala Gln
Ile Phe Lys Ala
Ile Phe Gln Ala
Ile Lys Ala Phe
Ile Lys Phe Ala
Ile Lys Met Ser
Ile Lys Ser Met
Ile Met Lys Ser
Ile Met Ser Lys
Ile Gln Ala Phe
Ile Gln Phe Ala
Ile Ser Lys Met
Ile Ser Met Lys
Lys Ala Phe Ile
Lys Ala Phe Leu
Lys Ala Ile Phe
Lys Ala Leu Phe
Lys Ala Pro Tyr
Lys Ala Tyr Pro
Lys Phe Ala Ile
Lys Phe Ala Leu
Lys Phe Ile Ala
Lys Phe Leu Ala
Lys Phe Pro Ser
Lys Phe Ser Pro
Lys His Pro Pro
Lys Ile Ala Phe
Lys Ile Phe Ala
Lys Ile Met Ser
Lys Ile Ser Met
Lys Leu Ala Phe
Lys Leu Phe Ala
Lys Leu Met Ser
Lys Leu Ser Met
Lys Met Ile Ser
Lys Met Leu Ser
Lys Met Ser Ile
Lys Met Ser Leu
Lys Met Thr Val
Lys Met Val Thr
Lys Pro Ala Tyr
Lys Pro Phe Ser
Lys Pro His Pro
Lys Pro Pro His
Lys Pro Ser Phe
Lys Pro Tyr Ala
Lys Ser Phe Pro
Lys Ser Ile Met
Lys Ser Leu Met
Lys Ser Met Ile
Lys Ser Met Leu
Lys Ser Pro Phe
Lys Thr Met Val
Lys Thr Val Met
Lys Val Met Thr
Lys Val Thr Met
Lys Tyr Ala Pro
Lys Tyr Pro Ala
Leu Ala Phe Lys
Leu Ala Phe Gln
Leu Ala Lys Phe
Leu Ala Gln Phe
Leu Phe Ala Lys
Leu Phe Ala Gln
Leu Phe Lys Ala
Leu Phe Gln Ala
Leu Lys Ala Phe
Leu Lys Phe Ala
Leu Lys Met Ser
Leu Lys Ser Met
Leu Met Lys Ser
Leu Met Ser Lys
Leu Gln Ala Phe
Leu Gln Phe Ala
Leu Ser Lys Met
Leu Ser Met Lys
Met Ile Lys Ser
Met Ile Ser Lys
Met Lys Ile Ser
Met Lys Leu Ser
Met Lys Ser Ile
Met Lys Ser Leu
Met Lys Thr Val
Met Lys Val Thr
Met Leu Lys Ser
Met Leu Ser Lys
Met Ser Ile Lys
Met Ser Lys Ile
Met Ser Lys Leu
Met Ser Leu Lys
Met Thr Lys Val
Met Thr Val Lys
Met Val Lys Thr
Met Val Thr Lys
Asn Phe Val Val
Asn Val Phe Val
Asn Val Val Phe
Pro Ala Lys Tyr
Pro Ala Tyr Lys
Pro Phe Lys Ser
Pro Phe Ser Lys
Pro His Lys Pro
Pro His Pro Lys
Pro Lys Ala Tyr
Pro Lys Phe Ser
Pro Lys His Pro
Pro Lys Pro His
Pro Lys Ser Phe
Pro Lys Tyr Ala
Pro Pro His Lys
Pro Pro Lys His
Pro Ser Phe Lys
Pro Ser Lys Phe
Pro Tyr Ala Lys
Pro Tyr Lys Ala
Gln Ala Phe Ile
Gln Ala Phe Leu
Gln Ala Ile Phe
Gln Ala Leu Phe
Gln Phe Ala Ile
Gln Phe Ala Leu
Gln Phe Ile Ala
Gln Phe Leu Ala
Gln Ile Ala Phe
Gln Ile Phe Ala
Gln Leu Ala Phe
Gln Leu Phe Ala
Arg Phe Gly Val
Arg Phe Val Gly
Arg Gly Phe Val
Arg Gly Val Phe
Arg Thr Thr Thr
Arg Val Phe Gly
Arg Val Gly Phe
Ser Phe Lys Pro
Ser Phe Pro Lys
Ser Ile Lys Met
Ser Ile Met Lys
Ser Lys Phe Pro
Ser Lys Ile Met
Ser Lys Leu Met
Ser Lys Met Ile
Ser Lys Met Leu
Ser Lys Pro Phe
Ser Leu Lys Met
Ser Leu Met Lys
Ser Met Ile Lys
Ser Met Lys Ile
Ser Met Lys Leu
Ser Met Leu Lys
Ser Pro Phe Lys
Ser Pro Lys Phe
Thr Lys Met Val
Thr Lys Val Met
Thr Met Lys Val
Thr Met Val Lys
Thr Arg Thr Thr
Thr Thr Arg Thr
Thr Thr Thr Arg
Thr Val Lys Met
Thr Val Met Lys
Val Phe Gly Arg
Val Phe Asn Val
Val Phe Arg Gly
Val Phe Val Asn
Val Gly Phe Arg
Val Gly Arg Phe
Val Lys Met Thr
Val Lys Thr Met
Val Met Lys Thr
Val Met Thr Lys
Val Asn Phe Val
Val Asn Val Phe
Val Arg Phe Gly
Val Arg Gly Phe
Val Thr Lys Met
Val Thr Met Lys
Val Val Phe Asn
Val Val Asn Phe
Tyr Ala Lys Pro
Tyr Ala Pro Lys
Tyr Lys Ala Pro
Tyr Lys Pro Ala
Tyr Pro Ala Lys
Tyr Pro Lys Ala
gentamicin
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use S - Sensory organs > S03 - Ophthalmological and otological preparations > S03A - Antiinfectives > S03AA - Antiinfectives J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors C254 - Anti-Infective Agent > C258 - Antibiotic
PC(O-16:2/0:0)[U]
1'-O-Acetylpaxilline
P-Decyloxybenzylidene p-Aminocinnamic Acid l-2-Methylbutyl Ester
(E)-7-[2-morpholin-4-yl-3-oxo-5-[(4-phenylphenyl)methoxy]cyclopentyl]hept-4-enoic acid
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
Gentamycin C1
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06A - Antibiotics for topical use S - Sensory organs > S03 - Ophthalmological and otological preparations > S03A - Antiinfectives > S03AA - Antiinfectives J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins S - Sensory organs > S02 - Otologicals > S02A - Antiinfectives > S02AA - Antiinfectives D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors
(3S,10R,13S)-3-[[4-(2-hydroxyethoxy)phenyl]methyl]-13-[(2S)-2-hydroxypentyl]-4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] octadeca-9,12-dienoate
1-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine
[(2R)-2,3-dihydroxypropyl] 2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]ethyl hydrogen phosphate
(E)-7-[3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid
(5Z)-7-[(1R)-2-[(1E,3S)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopent-2-en-1-yl]hept-5-enoylcarnitine
(5Z)-7-[(1R,2E,5S)-5-Hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine
(5Z)-7-{2-[(1E,3R)-3-Hydroxyoct-1-en-1-yl]-5-oxocyclopent-1-en-1-yl}hept-5-enoylcarnitine
(13E)-4,8-dihydroxy-5,5,7,9-tetramethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
2-azaniumylethyl (2R)-3-hydroxy-2-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propyl phosphate
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methylurea
[(1S)-7-methoxy-2-[(2-methoxyphenyl)methyl]-9-methyl-1-propyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(4Z)-7-{5-[([1,1-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid
(E)-7-[(1R,2R,3S,5S)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-1-methylurea
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methylurea
N-[[(2S,3S)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide
N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylacetamide
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide
N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylacetamide
N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylacetamide
1-[(1S)-1-(hydroxymethyl)-7-methoxy-1-[(2-methoxyphenyl)methyl]-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
2-(dimethylamino)-1-[(1S)-1-(hydroxymethyl)-7-methoxy-2-(3-pyridinylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
3-(3,5-dimethyl-4-isoxazolyl)-1-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-1-methylurea
N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylacetamide
N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylacetamide
N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylacetamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(4-phenylanilino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide
N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylacetamide
[(1S)-2-(cyclopropylmethyl)-1-[(4-fluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
1-[(1R)-1-(hydroxymethyl)-7-methoxy-1-[(2-methoxyphenyl)methyl]-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
2-(dimethylamino)-1-[(1R)-1-(hydroxymethyl)-7-methoxy-2-(3-pyridinylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
[(1S)-2-(1,3-benzodioxol-5-ylmethyl)-7-methoxy-1-propyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
N-hexanoylsphingosine 1-phosphate
A ceramide 1-phosphate in which the ceramide N-acyl group is specified as hexanoyl.
(2S,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]-2-oxanyl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9Z,12Z)-octadeca-9,12-dienoate
[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-aminoethyl [2-hydroxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] hydrogen phosphate
(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)dodec-4-ene-1-sulfonic acid
3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]dodecane-1-sulfonic acid
3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]decane-1-sulfonic acid
3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]undecane-1-sulfonic acid
(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)undec-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)dec-4-ene-1-sulfonic acid
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (6E,9E)-octadeca-6,9-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] acetate
6,7,7,10,10,13-Hexamethylspiro[1,8-dihydropyrano[2,3-g]indole-3,11-3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane]-2,9,14-trione
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9E,12E)-octadeca-9,12-dienoate
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9E,12E)-octadeca-9,12-dienoate
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (2E,4E)-octadeca-2,4-dienoate
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9E,11E)-octadeca-9,11-dienoate
2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)trideca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(butanoylamino)-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-acetamido-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
1-Linoleoyl-sn-glycero-3-phosphoethanolamine
A 1-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as linoleoyl.
1-linoleoyl-sn-glycero-3-phosphoethanolamine zwitterion
A lysophosphatidylethanolamine zwitterion obtained by transfer of a proton from the phosphate group to the amino group of 1-linoleoyl-sn-glycero-3-phosphoethanolamine. Major species at pH 7.3.
2-linoleoyl-sn-glycero-3-phosphoethanolamine
A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as linoleoyl.
(Z)-7-[(1R,2R,5S)-2-morpholin-4-yl-3-oxo-5-[(4-phenylphenyl)methoxy]cyclopentyl]hept-4-enoic acid
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
(4Z)-7-[(1S,2S,5R)-5-[([1,1-Biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl]hept-4-enoic acid
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
1-(1Z,12Z-nonadecadienyl)-sn-glycero-3-phosphoethanolamine
lysophosphatidylcholine 15:2
A lysophosphatidylcholine in which the remaining acyl group (position unspecified) contains 15 carbons and 2 double bonds.
lysophosphatidylethanolamine 18:2
A lysophosphatidylethanolamine in which the acyl group (position not specified) contains 18 carbons and 2 double bonds.
lysophosphatidylethanolamine (18:2/0:0)
A lysophosphatidylethanolamine 18:2 in which the acyl group is located at position 1.
lysophosphatidylethanolamine (0:0/18:2)
A lysophosphatidylethanolamine 18:2 in which the acyl group is located at position 2.
PF 1163A
A macrolide antibiotic that is 4,10-dimethyl-1-oxa-4-azacyclotridecane-2,5-dione substituted by a 4-(2-hydroxyethoxy)benzyl group at position 3 and a (2R)-2-hydroxypentyl group at position 13 (the 3S,10R,13S stereoisomer). It is isolated from Penicillium sp.PF1163 and exhibits antifungal activity against the pathogenic fungal strain Candida albicans TIMM1768.
2-linoleoyl-sn-glycero-3-phosphoethanolamine zwitterion
A 2-acyl-sn-glycero-3-phosphoethanolamine zwitterion obtained by transfer of a proton from the phosphate to the amino group of 2-linoleoyl-sn-glycero-3-phosphoethanolamine; major species at pH 7.3.
PE(18:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LPC(16:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
